Feed CASBF
Summary
25 / 100 · Bulios Score
Valuation 18Growth 16Profitability 24Quality 4Debt 80Stability 20
What speaks for it
- It holds more cash than debt: ¥1.13B against ¥929.2M.
- It passes 9 of the 9 points of the Piotroski financial health test.
What to watch
- Revenue growth is slowing: 0.0% a year over the last 3 years against 111% over 5 years.
- It reports a profit, yet spends more cash than it brings in.
- It missed profit estimates 5 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveP/E today 266.4
Biotechnology industry median
Today you pay 266.4 CNY for 1 CNY of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (CNY)
2021202220232024202520262027
Diluted EPS (CNY)
2021202220232024202520262027
- Analyst estimate
Revenue grew by 111% a year over 5 years. Over the last 3 years it grew by 0.0% a year.
Growth in detailDoes it make money?
PoorlyWhere 100 CNY of revenue goes
- Cost of sales 34 CNY
- Research and development 19 CNY
- Sales and administration 54 CNY
- Taxes and other -6.5 CNY
- Net profit 2.4 CNY
Net profit, industry median (Biotechnology) -7.1 CNY
Out of every 100 CNY of revenue, 2.4 CNY is left as net profit.
Profitability in detailIs it financially healthy?
YesCash and short-term investments ¥1.77B
Debt ¥929.2M
Free cash flow over 12 months -¥63.6M
Over the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.